Expert Review of Anti-infective Therapy · 2020 · 44 citations · 68 references
MedicineInfectious DiseasesPharmacologyImmunizationInfectious Disease PharmacotherapyVaccinologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyTreatmentVaccinationVaccine-preventable DiseasesCoronavirus Infection PreventionCoronavirus VaccinesHydroxychloroquine TherapyHydroxychloroquine TreatmentPublic Health ProtectionSars-cov-2 InfectionTreatment Of Coronavirus Infections
INTRODUCTION: Over the last few months, coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus SARS-CoV-2 has posed a serious threat to public health on a global scale. Given the current lack of an effective vaccine, several drugs have been repurposed for treatment and prophylaxis of COVID-19 in an attempt to find an effective cure. AREAS COVERED: The antimalarial drug hydroxychloroquine (HCQ) initially garnered widespread attention following the publication of preliminary results showing that this drug exerts an anti-SARS-CoV-2 activity in vitro. EXPERT OPINION: To date, clinical evidence suggests lack of benefit from HCQ use for the treatment of hospitalized patients with COVID-19. In such patients, HCQ also appears to be associated with an increased risk of QT interval prolongation and potentially lethal ventricular arrhythmias. Therefore, FDA has recently revoked the Emergency Use Authorization (EUA) for emergency use of HCQ and chloroquine to treat COVID-19. Conversely, whether HCQ use may represent an effective prophylactic strategy against COVID-19 is a separate question that still remains to be answered. In addition, relevant aspects regarding the potential risks and benefits of HCQ need to be clarified, in pursuit of a rational use of this drug in the COVID-19 pandemic era.
68
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang et al. · Nature · 2020 · 23.3K citations · Full text
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell · 2020 · 9.1K citations · Full text
Remdesivir for the Treatment of Covid-19 — Final Report
John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.7K citations · Full text
Philippe Gautret, Jean‐Christophe Lagier, Philippe Parola et al. · International Journal of Antimicrobial Agents · 2020 · 5K citations · Full text